Success Metrics

Clinical Success Rate
93.9%

Based on 92 completed trials

Completion Rate
94%(92/98)
Active Trials
5(4%)
Results Posted
55%(51 trials)
Terminated
6(5%)

Phase Distribution

Ph early_phase_1
3
3%
Ph phase_3
16
13%
Ph phase_2
32
27%
Ph phase_1
14
12%
Ph not_applicable
10
8%
Ph phase_4
35
29%

Phase Distribution

17

Early Stage

32

Mid Stage

51

Late Stage

Phase Distribution110 total trials
Early Phase 1First-in-human
3(2.7%)
Phase 1Safety & dosage
14(12.7%)
Phase 2Efficacy & side effects
32(29.1%)
Phase 3Large-scale testing
16(14.5%)
Phase 4Post-market surveillance
35(31.8%)
N/ANon-phased studies
10(9.1%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

90.2%

92 of 102 finished

Non-Completion Rate

9.8%

10 ended early

Currently Active

5

trials recruiting

Total Trials

119

all time

Status Distribution
Active(9)
Completed(92)
Terminated(10)
Other(8)

Detailed Status

Completed92
unknown8
Terminated6
Not yet recruiting4
Withdrawn4
Recruiting4

Development Timeline

Analytics

Development Status

Total Trials
119
Active
5
Success Rate
93.9%
Most Advanced
Phase 4

Trials by Phase

Early Phase 13 (2.7%)
Phase 114 (12.7%)
Phase 232 (29.1%)
Phase 316 (14.5%)
Phase 435 (31.8%)
N/A10 (9.1%)

Trials by Status

not_yet_recruiting43%
completed9277%
withdrawn43%
active_not_recruiting11%
unknown87%
recruiting43%
terminated65%

Recent Activity

Clinical Trials (119)

Showing 20 of 119 trialsScroll for more
NCT07316296Phase 3

Pharmacologically Modulating the Noradrenergic Arousal System to Reduce Freezing of Gait in Parkinson's Disease: a Multi-centre and Multi-modal Approach

Recruiting
NCT06573970Phase 4

Atomoxetine and Executive Function in PTSD

Not Yet Recruiting
NCT02879136Early Phase 1

TAME-PD - Physical Therapy, Atomoxetine and, Methylphenidate, to Enhance Gait and Balance in Parkinson's Disease

Completed
NCT03919955Phase 2

A Novel Pharmacological Therapy for Obstructive Sleep Apnea

Completed
NCT07239791Not Applicable

Role of the Noradrenergic System in the Regulation of Learning Dynamics: Evaluation of the Effect of a Low-dose Selective Noradrenaline Reuptake Inhibitor (NOISYXETINE)

Recruiting
NCT00498173Phase 3

Effectiveness of Atomoxetine in Treating ADHD Symptoms in Children and Adolescents With Autism

Completed
NCT00262470Phase 1

Treatment of Orthostatic Intolerance

Active Not Recruiting
NCT03460210

Bariatric Surgery and Pharmacokinetics of Atomoxetine

Completed
NCT04132557

A Study on Suicidality, Psychosis or Substance Abuse With Methylphenidate, Atomoxetine, Amphetamine/Dextroamphetamine or Lisdexamfetamine

Completed
NCT04565288Phase 2

Enhancing the Effects of Adolescent Alcohol Treatment With Atomoxetine

Completed
NCT06899178Phase 2

Atomoxetine in Melanocortin Obesity Syndrome

Not Yet Recruiting
NCT06841666Early Phase 1

Evaluating the Efficacy of Atomoxetine in Reducing Primary Nocturnal Enuresis in Children With ADHD: A Randomized, Placebo-Controlled Study

Not Yet Recruiting
NCT03808740Phase 1

Orthostatic Intolerance After Bariatric Surgery

Terminated
NCT06542887Phase 2

Black Seed Oil in ADHD

Not Yet Recruiting
NCT03781765Phase 4

Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk

Recruiting
NCT03936491Not Applicable

The Neuroprotective Effects of Methylphenidate and Atomoxetine in Children With ADHD: A Lipidomic Study

Completed
NCT04354103Phase 2

Atomoxetine in Patients With Tourette's Syndrome

Terminated
NCT05550246Phase 1

Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy

Unknown
NCT00254462Phase 4

Atomoxetine for Treating Attention Deficit Hyperactivity Disorder in Young Children

Completed
NCT04445688Phase 2

Crossover Trial of AD036 in Obstructive Sleep Apnea

Completed

Drug Details

Intervention Type
DRUG
Total Trials
119